{"id":195491,"date":"2026-08-11T12:42:05","date_gmt":"2026-08-11T07:12:05","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=195491"},"modified":"2026-08-11T12:42:06","modified_gmt":"2026-08-11T07:12:06","slug":"windlas-biotech-q1-results-fy27-pat-17-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/","title":{"rendered":"Windlas Biotech Q1 FY27 Results: Revenue Rs 248 Cr, PAT Rs 17 Cr and Key Highlights"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Windlas Biotech Q1 FY27 results declared August 10, 2026. Revenue Rs 248 Cr (+18.09% YoY). PAT Rs 17 Cr (-0.07% YoY). CMP Rs 839.65 (-4.89%).<\/em><\/p>\n<p>Windlas Biotech Q1 FY27 results were declared on August 10, 2026 on a standalone basis. Revenue expanded +18.09% YoY to Rs 248 Cr from Rs 210 Cr in Q1 FY26. The broader <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index reflected mixed sentiment during the quarter.<\/p>\n<p>Operating profit stood at Rs 19 Cr (+2.08% YoY). PAT came in at Rs 17 Cr (-0.07% YoY), reflecting the key financial metrics of Windlas Biotech Q1 FY27 results.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=windlas-biotech-q1-fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Windlas_Biotech_Q1_FY27_Financial_Highlights\" title=\"Windlas Biotech Q1 FY27 Financial Highlights\">Windlas Biotech Q1 FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Windlas_Biotech_Q1_FY27_Performance_Analysis\" title=\"Windlas Biotech Q1 FY27 Performance Analysis\">Windlas Biotech Q1 FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Key_Business_Factors_in_Windlas_Biotech_Q1_FY27_Results\" title=\"Key Business Factors in Windlas Biotech Q1 FY27 Results\">Key Business Factors in Windlas Biotech Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Revenue_Expansion_in_Q1_FY27\" title=\"Revenue Expansion in Q1 FY27\">Revenue Expansion in Q1 FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Operating_Margin_Performance\" title=\"Operating Margin Performance\">Operating Margin Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#PAT_Trajectory_and_Profitability\" title=\"PAT Trajectory and Profitability\">PAT Trajectory and Profitability<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#FY27_Outlook_for_Windlas_Biotech\" title=\"FY27 Outlook for Windlas Biotech\">FY27 Outlook for Windlas Biotech<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Windlas_Biotech_Stock_Performance_After_Q1_FY27_Results\" title=\"Windlas Biotech Stock Performance After Q1 FY27 Results\">Windlas Biotech Stock Performance After Q1 FY27 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Key_Risks_for_Windlas_Biotech\" title=\"Key Risks for Windlas Biotech\">Key Risks for Windlas Biotech<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Sector-Specific_Risks\" title=\"Sector-Specific Risks\">Sector-Specific Risks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Valuation_and_Earnings_Risk\" title=\"Valuation and Earnings Risk\">Valuation and Earnings Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Operational_and_Financial_Risk\" title=\"Operational and Financial Risk\">Operational and Financial Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Frequently_Asked_Questions_on_Windlas_Biotech_Q1_FY27_Results\" title=\"Frequently Asked Questions on Windlas Biotech Q1 FY27 Results\">Frequently Asked Questions on Windlas Biotech Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#When_were_Windlas_Biotech_Q1_FY27_results_declared\" title=\"When were Windlas Biotech Q1 FY27 results declared?\">When were Windlas Biotech Q1 FY27 results declared?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#What_was_Windlas_Biotech_revenue_in_Q1_FY27\" title=\"What was Windlas Biotech revenue in Q1 FY27?\">What was Windlas Biotech revenue in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#What_was_Windlas_Biotech_PAT_in_Q1_FY27\" title=\"What was Windlas Biotech PAT in Q1 FY27?\">What was Windlas Biotech PAT in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#Did_Windlas_Biotech_declare_a_dividend_in_Q1_FY27\" title=\"Did Windlas Biotech declare a dividend in Q1 FY27?\">Did Windlas Biotech declare a dividend in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#What_is_the_FY27_outlook_for_Windlas_Biotech\" title=\"What is the FY27 outlook for Windlas Biotech?\">What is the FY27 outlook for Windlas Biotech?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-q1-results-fy27-pat-17-crore\/#How_did_Windlas_Biotech_stock_react_to_Q1_FY27_results\" title=\"How did Windlas Biotech stock react to Q1 FY27 results?\">How did Windlas Biotech stock react to Q1 FY27 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Windlas_Biotech_Q1_FY27_Financial_Highlights\"><\/span><strong>Windlas Biotech Q1 FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px;\">\n<thead>\n<tr style=\"background: #0A0E1A; color: #fff;\">\n<th style=\"padding: 10px; text-align: left; border: 1px solid #DDD;\">Metric<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">Q1 FY27 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">Q1 FY26 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Windlas Biotech Revenue<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">248<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">210<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: green;\">+18.09%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Operating Profit<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">19<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">19<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: green;\">+2.08%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Net Profit (PAT)<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">17<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">17<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: red;\">-0.07%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Reporting Basis<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\" colspan=\"3\">Standalone<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Windlas_Biotech_Q1_FY27_Performance_Analysis\"><\/span><strong>Windlas Biotech Q1 FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data on This Stock<\/strong><\/a><\/p>\n<p>Windlas Biotech Q1 FY27 results reflect modest fundamentals. Revenue momentum were evident with the top line reaching Rs 248 Cr for the April to June 2026 quarter.<\/p>\n<p>Operating profit expanded +2.08% YoY. PAT of Rs 17 Cr reflects -0.07% YoY movement. Investors tracking Windlas Biotech Q1 FY27 results will note these as key FY27 milestones.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_in_Windlas_Biotech_Q1_FY27_Results\"><\/span><strong>Key Business Factors in Windlas Biotech Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Expansion_in_Q1_FY27\"><\/span><strong>Revenue Expansion in Q1 FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Windlas Biotech Q1 FY27 results show revenue expanding +18.09% YoY to Rs 248 Cr from Rs 210 Cr in Q1 FY26. Volume-led growth and market share gains in the Pharmaceuticals segment drove the uptick.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operating_Margin_Performance\"><\/span><strong>Operating Margin Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Operating profit in Windlas Biotech Q1 FY27 results stood at Rs 19 Cr (+2.08% YoY). Better cost absorption and product mix improvement contributed to the operating performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Trajectory_and_Profitability\"><\/span><strong>PAT Trajectory and Profitability<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>PAT in Windlas Biotech Q1 FY27 results was Rs 17 Cr (-0.07% YoY), reflecting near-term operational challenges.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No dividend was declared alongside Windlas Biotech Q1 FY27 results. Earnings are being channelled toward operational reinvestment and working capital.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FY27_Outlook_for_Windlas_Biotech\"><\/span><strong>FY27 Outlook for Windlas Biotech<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Following Windlas Biotech Q1 FY27 results, management has focused on a recovery-driven strategy centred on cost reduction, revenue diversification, and return to profitability in the pharmaceuticals segment. Investors tracking Windlas Biotech Q1 FY27 results should consult a SEBI-registered financial advisor.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Windlas_Biotech_Stock_Performance_After_Q1_FY27_Results\"><\/span><strong>Windlas Biotech Stock Performance After Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Windlas Biotech live price and get daily stock recommendations.<\/em><\/p>\n<p>Windlas Biotech shares were trading lower at Rs 839.65 (-4.89%) on August 10, 2026, reflecting investor sentiment on Windlas Biotech Q1 FY27 results and the near-term sector outlook. The CMP of Rs 839.65 on the results date reflects broader sentiment toward the pharmaceuticals space.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Windlas_Biotech\"><\/span><strong>Key Risks for Windlas Biotech<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Sector-Specific_Risks\"><\/span><strong>Sector-Specific Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>USFDA regulatory actions, generic pricing pressure, and API cost inflation remain core risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Earnings_Risk\"><\/span><strong>Valuation and Earnings Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sustained margin compression and limited near-term earnings visibility may delay re-rating.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operational_and_Financial_Risk\"><\/span><strong>Operational and Financial Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Working capital intensity and cash conversion cycle elongation could strain standalone cash flows.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Windlas Biotech Q1 FY27 results reflect modest performance with revenue at Rs 248 Cr and PAT at Rs 17 Cr on a Standalone basis. Sector tailwinds and operational discipline will shape the FY27 trajectory. Investors should review management commentary before taking any position.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Windlas_Biotech_Q1_FY27_Results\"><\/span><strong>Frequently Asked Questions on Windlas Biotech Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Windlas_Biotech_Q1_FY27_results_declared\"><\/span><strong>When were Windlas Biotech Q1 FY27 results declared?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Windlas Biotech Q1 FY27 results were declared on August 10, 2026, covering the April\u2013June 2026 quarter on a Standalone basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Windlas_Biotech_revenue_in_Q1_FY27\"><\/span><strong>What was Windlas Biotech revenue in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue in Windlas Biotech Q1 FY27 results was Rs 248 Cr, +18.09% YoY from Rs 210 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Windlas_Biotech_PAT_in_Q1_FY27\"><\/span><strong>What was Windlas Biotech PAT in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Net profit in Windlas Biotech Q1 FY27 results was Rs 17 Cr (-0.07% YoY).<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Windlas_Biotech_declare_a_dividend_in_Q1_FY27\"><\/span><strong>Did Windlas Biotech declare a dividend in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No dividend was announced alongside Windlas Biotech Q1 FY27 results. Refer to official NSE and BSE announcements for future dividend updates.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_FY27_outlook_for_Windlas_Biotech\"><\/span><strong>What is the FY27 outlook for Windlas Biotech?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Management has guided operational restructuring and return to profitability for FY27. Sector demand and execution will be key monitorables.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_Windlas_Biotech_stock_react_to_Q1_FY27_results\"><\/span><strong>How did Windlas Biotech stock react to Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Windlas Biotech shares were lower at Rs 839.65 (-4.89%) on August 10, 2026. Consult a SEBI-registered financial advisor before acting on price movements.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Windlas Biotech Q1 FY27 results: Revenue Rs 248 Cr (+18.09% YoY), PAT Rs 17 Cr (-0.07% YoY). Key highlights, analysis and FY27 outlook.<\/p>\n","protected":false},"author":28,"featured_media":195490,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-195491","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["195490"],"_edit_lock":["1786432330:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["70"],"rank_math_title":["Windlas Biotech Q1 FY27 Results: Revenue, PAT &amp; Key Highlights"],"rank_math_description":["Windlas Biotech Q1 FY27 results: Revenue Rs 248 Cr (+18.09% YoY), PAT Rs 17 Cr (-0.07% YoY). Key highlights, analysis and FY27 outlook."],"rank_math_focus_keyword":["Windlas Biotech Q1 FY27 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["35849"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/windlas-biotech-q1-results-fy27-pat-17-crore.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/195491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=195491"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/195491\/revisions"}],"predecessor-version":[{"id":196541,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/195491\/revisions\/196541"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/195490"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=195491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=195491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=195491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}